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Abstract In addition to their conventional chaperon activity, numerous studies 
have reported that heat shock protein 70 (HSP0) exhibit immune properties and 
especially the capacity (i) to induce the presentation and cross-presentation of asso-
ciated or client proteins and, (ii) to control myeloid cell activation. Several studies 
were focused on the identification of HSP70-binding elements that contribute to 
their immune properties. A general consensus was reached on the nature of the 
endocytic receptors involved in the internalization of extracellular HSP70 with 
belong, for most of them, to the innate immunity receptor family. However, the 
nature of signaling receptors recruited by HSP70 remains unclear, because the stim-
ulatory versus regulatory properties of HSP70 remains a subject of debate. 
Nevertheless, these unique immune properties allowed developing innovative pro-
phylactic and therapeutic vaccines, especially in the treatment of cancers and 
chronic viral infections. Although HSP70 constitute potent vaccine vehicles in dif-
ferent preclinical models, clinical studies remain disappointing. The fact that the 
immune properties of HSP70 have not been totally clarified may explain their rela-
tive efficacy in human. In this review are presented the main immune properties of 
HSP70 related to the HSP70-binding elements identified to date, and discuss our 
current knowledge on their intrinsic immune properties.
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Abbreviations
A2M alpha2 macroglobulin
Ac-LDL acetylated low-density lipoprotein
ADP adenosine dipohosphate
AGE advanced glycation end product
AIF apoptosis inducing factor
APAf-1 apoptotic peptidase activating factor 1
APC antigen-presenting cell
APOER apolipoprotein E receptor
ATP adenosine triphosphate
Bax Bcl-2-associated X protein
BCR B cell receptor
BiP binding immunoglobulin protein
CCL C-C motif ligand
CCR C-C chemokine receptor
CD cluster of differentiation
CLEC8A C-type lectin domain family 8 member A
CLEVER-1 common lymphatic endothelial and vascular endothelial receptor-1
CTL cytotoxic T cell
DAMP danger-associated molecular pattern
DC-SIGN dendritic cell-specific ICAM-grabbing non-integrin
EBV Epstein-Barr virus
EGF-like and link domain-containing scavenger receptor-1
ER endoplasmic reticulum
ERK Extracellular signal-regulated kinases
FAT fatty acid translocase
FEEL-1 fasciclin EGF-like laminin-type
HBV hepatitis B virus
HCV hepatitis C virus
Her2/Neu human epidermal growth factor receptor 2/proto-oncogene Neu
HLA human leukocyte antigen
HMGB1 high–mobility group box 1
HPV human papilloma virus
HSP heat shock protein
IFN interferon
IL interleukin
IRAK IL-1 receptor-associated kinase
IRE1α inositol requiring enzyme 1α
JAK Janus kinase
LBP LPS-binding protein
LDL low-density lipoprotein
LRP1 low density lipoprotein receptor-related protein 1
MAGE-1 melanoma-associated antigen 1
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Mart-1 melanoma antigen recognized by T-cells 1
MD2 myeloid differentiation factor 2
MDSC myeloid-derived suppressive cells
MHC major histocompatibility complex
MyD88 Myeloid differentiation primary response 88
NBD nucleotide-binding domain
NF-κB nuclear factor-kappa B
NK natural killer
Ox-LDL oxidized low-density lipoprotein
PAMP pathogen-associated molecular pattern
PDZK PDZ domain-containing protein 1
PRM pattern recognition molecule
PRR pattern recognition receptor
PSA prostate-specific antigen
PTX3 pentraxin 3
RAP receptor-associated protein
SBD substrate-binding domain
SIGLEC sialic-acid-binding immunoglobulin-like lectins
SP-D surfactant protein D
SREC scavenger receptor expressed by endothelial cells
STAT signal transducers and activators of transcription
TAB1 TAK1-binding protein 1
TAK1 TGFβ-activated kinase
TAM tumor-associated macrophages
TCR T cell receptor
Th helper T cell
TLR toll-like receptor
TNF tumor necrosis factor
TNFSF TNF superfamily
TRAF TNF receptor-associated factor
Trp2 tyrosinase-related protein 2
TSP-1 thrombospondin 1
 Introduction
Heat shock proteins (HSP) are involved in 3D-folding of newly synthesized proteins 
and protect them against endogenous and exogenous assaults. Besides their classi-
cal biochemical properties, several studies have demonstrated that HSP70, one of 
the largest and highly conserved family of HSP, exhibit intrinsic immune properties. 
The potential immune properties of HSP70 were first hypothesized in the 1970s by 
showing that proteins with an apparent molecular weight of 70 kDa and isolated 
from tumor cells may induce a protective immune response in vivo, in the absence 
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of adjuvant. Thereafter, a huge quantity of studies aimed at deciphering, in vivo and 
in vitro, the biological mechanisms involved in the immune properties of HSP. Most 
of the immune properties of HSP were first elucidated for gp96 (HSP90B1), a mem-
ber of the HSP90 family, and thereafter for HSP70. One of the most remarkable 
immune properties of HSP70 is their ability to mediate the cross-presentation of 
exogenous antigens and to initiate protective antitumor immune responses. In agree-
ment with the cross-presentation process, HSP70 have been shown to interact with 
different immune receptors, especially innate receptors. However, the exact nature 
of the endocytic and signaling receptors engaged by HSP70, as well as whether 
HSP70 exhibit stimulatory or regulatory immune properties, remain a subject of 
debate. Nevertheless, and whatever the mechanism involved, HSP70 constitute 
interesting vehicles to induce, in vivo, antigen-specific cytotoxic responses. This 
review thus addresses the immune properties of HSP70, with a focus on the innate 
immune receptors engaged, and the consequences on vaccine strategies.
 HSP70 Family of Chaperones
 Common Features of HSP70
The 70 kDa heat shock proteins (HSP70s) constitute a family of highly conserved 
proteins that are ubiquitously expressed in prokaryotes and eukaryotes. Prokaryotes 
express three HSP70 proteins (DnaK, HscA (Hsc66), and HscC (Hsc62)) whereas 
eukaryotes express several HSP70s. As an example, the human family comprises 13 
proteins, that differ from each other by their amino acid sequence, their levels of 
expression and their localization (Radons 2016). The mostly expressed inducible 
human HSP70s are Hsp70–1 (encoded by the HSPA1A gene) and Hsp70–2 
(HSPA1B); these two genes are closely located in the genome (Brocchieri et  al. 
2008). In line with the topic of this review, it is important to mention human HSP70–
14 (also referred to as Hsp70L1), a stress-induced HSP identified in dendritic cells, 
exhibits potent immunostimulatory properties by favoring Th1 responses (Wan 
et al. 2004). Interestingly, the levels of HSP0L1 are elevated in some tumors (Yang 
et al. 2015).
HSP70s display a common functional domain structure: (i) a 44 kDa N-terminal 
nucleotide binding domain (NBD) that binds and hydrolyzes ATP, (ii) a middle 
protease-sensitive domain and, (iii) a 28 kDa C-terminal substrate-binding domain 
(SBD) that can interact with 6–9 amino acid-long peptides; SBD has preferential 
affinity for neutral and hydrophobic amino acids. HSP70s are monomeric chaper-
ons that participate, in physiological situations, to the folding of neo-synthesized 
proteins, to their transport and to the assembly of multi-protein complexes. The 
binding/release of polypeptides is dependent on the ATPase activity: the ADP- and 
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ATP-bound states favor peptide binding and release, respectively. HSP70s also reg-
ulate the activity of proteins and prevent their aggregation. Indeed, HSP70s exhibit 
an « unfoldase » activity, meaning that they recognize unfolded or aggregated pro-
teins and unfold them before native refolding (Radons 2016). The expression of 
HSP70s is strongly upregulated by cellular stress, such as heat, toxic chemicals 
(such as heavy metals), ischemia, irradiations, infection, inflammation and nutrient 
deprivation. In stressed cells (induced by endogenous or exogenous challenges), 
HSP70s promote cell survival and allow cells to restore cellular homeostasis.
HSP70s act as anti-apoptoti proteins via their capacity to prevent mitochondrial 
translocation and activation of Bax (Yang et al. 2012) and to inhibit assembly of the 
death-inducing signaling complexes (Guo et  al. 2005). HSP70s also inhibit the 
activity of different pro-apoptotic molecules (such as Apaf-1, AIF and caspase 3) 
(Beere et al. 2000; Ravagnan et al. 2001). HSP70s can protect cells against apopto-
sis induced by endoplasmic reticulum stress via their interaction with the ER stress 
sensor protein IRE1α (Wei et al. 2013).
 Intracellular, Membrane and Extracellular HSP70
As the other HSP, members of the HSP70 family are mainly expressed in intracel-
lular compartments, including cytosol, endoplasmic reticulum (such as binding 
immunoglobulin protein (BiP) or Grp78) and mitochondria (mtHsp70 or Grp75), to 
exert their chaperon activities. Nevertheless, HSP70s can be expressed at the mem-
brane surface or present, in a soluble form, in different biological fluids. Membrane 
HSP70s (mHSP70) accumulate at the surface of infected and tumor cells but not 
living cells (Multhoff et al. 1995; Multhoff and Hightower 1996; Poccia et al. 1996). 
Different mechanisms have been proposed to explain the membrane relocalization 
of proteins devoid of secretion signals, such as the release of secretory granules 
(Evdonin et al. 2004; Mambula and Calderwood 2006a, b) and of exosomes (Gastpar 
et al. 2005; Lancaster and Febbraio 2005). The apparently « passive » accumulation 
of HSP70 at the cell membrane appears similar to the one reported for other intra-
cellular molecules, such as PTX3 (Jaillon et al. 2009), or danger molecules, such as 
histones and nucleic acids (Cunin et al. 2016) that have also been reported to accu-
mulate at the surface of stressed cells. Accordingly, mHSP70 may have an impor-
tant role in the recognition of stressed and tumor cells by innate immune cells 
(Multhoff 2007; Radons and Multhoff 2005). Based on their biochemical proper-
ties, one can suspect that mHSP70 are associated to membrane proteins; however, 
to date, the nature of these putative mHSP70-associated molecules remains 
unknown.
Another explanation should be that extracellular HSP70s may bind to altered 
molecules, such as oxidized proteins, that are present at the surface of stressed cells, 
in a way similar to the one of bridging molecules (Henson 2017). HSP70s can be 
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released by numerous cell types in response to various stimuli (Campisi and Fleshner 
2003). Different ways of secretion of HSP70 have been described:
 – A passive release by necrotic cells (Fleshner and Johnson 2005),
 – The disruption of HSP70-containing secretory vesicles/exosomes released via a 
non-classical secretion pathway (MacKenzie et al. 2001) and,
 – A release via the secretion of lysosomal endosomes (Baraldi et al. 2004; Mambula 
and Calderwood 2006b).
HSP70s can be used as biomarkers. As an example, mHSP70s are considered as 
selective markers of aggressive tumors. Circulating HSP70 have been proposed as 
biomarkers of inflammation in healthy subjects (Gehrmann et al. 2014a; Marotta 
et al. 2007). HSP70s have been detected in the serum of patients suffering from 
cancer or chronic infection (Pockley et al. 2014) and are proposed as biomarkers of 
tumor outcome after treatment (Gehrmann et al. 2014a, b). These data suggest that 
the immune properties of HSP70s may depend not only on the nature of the chaper-
oned peptides but also on their localization. Indeed, membrane and extracellular 
HSP70 may influence the nature and amplitude of signals delivered to immune cells 
present in the close vicinity or at distance.
 HSP70 Induce Protective Immune Responses Against Tumors 
and Microbial Pathogens
Most of the studies on the use of HSP70s as vaccine vehicles have been performed 
in preclinical models of tumor growth. Nevertheless, and based on their vaccine 
potential, HSP70 have been also used for the induction of protective immune 
responses against microbes. In this paragraph, we focus on the antitumor immune 
responses induced by HSP70s.
 HSP70s Mediate Antigen Presentation and Cross Presentation
The pioneering studies by the group of PK Srivastava demonstrated that tumor- 
derived gp96 initiate protective tumor-specific CTL responses, suggesting that HSP 
may act as major tumor-rejection antigens (Suto and Srivastava 1995; Tamura et al. 
1997). This capacity to induce protective antitumor immune responses has been 
extended to other HSP families, especially HSP60 and HSP70 families (Castellino 
et  al. 2000). The capacity of HSP70s to induce protective antitumor immune 
responses was mainly reported in both prophylactic and therapeutic murine models 
of tumor development (reviewed in (Srivastava 2002). Moreover, HSP70s also 
induce cross-presentation of human tumor antigens (Castelli et  al. 2001; Milani 
et  al. 2002; Noessner 2006; Noessner et  al. 2002), the rationale for their use in 
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tumor vaccines in humans. In fact, numerous studies have clearly demonstrated that 
the specificity of the anti-tumor immune response was determined by the chaper-
oned peptides (Binder and Srivastava 2005; Ishii et al. 1999; Suto and Srivastava 
1995). Biochemical analysis have shown that peptides associated to HSP70 are very 
diverse, deriving from self-proteins, tumor, microbial or minor histocompatibility 
antigens (Srivastava 2002). As an example, HSP70s isolated from melanoma cell 
lines can chaperon peptides derived from the tumor antigens Mart-1, gp100, Trp2 
and gp100 (Castelli et al. 2001; Noessner et al. 2002).
According to the classical view of antigen presentation, antigen-derived peptides 
are presented into the MHC class I (MHC-I) and MHC class II (MHC-II) molecules 
of antigen-presenting cells (APC) to epitope-specific T cell receptors (TCR) 
expressed by CD8+ and CD4+ T cells, respectively. This interaction is the basis of 
the antigen-specificity of the adaptive immunity. Although different myeloid cells 
are able to present antigens to T cells (such as macrophages and neutrophils), den-
dritic cells are the only APC able to prime naive T cells and to initiate immune 
responses (Banchereau et al. 2000; Cella et al. 1997).
The process by which some exogenous antigens are endocytosed by APCs, gain 
access to the MHC class I pathway, and stimulate CD8+ T cells is called cross- 
presentation (Heath and Carbone 2001; Yewdell et al. 1999). Indeed, the classical 
view of antigen presentation claimed that exogenous antigens endocytosed by APC 
are mainly loaded into the MHC-II molecules for recognition by CD4+ T cells, 
while, in contrast, endogenous antigens (self and viral proteins) are loaded in the 
MHC-I molecules for recognition by CD8+ T cells. Antigen cross-presentation has 
revolutionized our view of the induction of antigen-specific immune responses and 
allowed to propose « conventional » vaccine approaches for the treatment of can-
cers. The HSP-mediated antigen cross-presentation is dependent on three essential 
mechanisms:
 – A receptor-mediated internalization of the antigens by professional APCs, espe-
cially dendritic cells,
 – The functional maturation and activation of professional APC, rendering them 
able to prime naive T cells and,
 – An intracellular trafficking allowing exogenous antigens/peptides to get access 
to the MHC-I presentation pathway.
One of the most important, and also most debated immune property of HSP, is 
their capacity to activate APCs. Indeed, the priming of CD8+ T cells by exogenous 
antigens requires that APC are fully activated (Banchereau et al. 2000), a status that 
may require CD4+ T cell help (Heath and Carbone 1999). The cross-presentation of 
an antigen by non-activated dendritic cells maintains or induces antigen-specific tol-
erance; this process is referred to as cross-tolerance. Ideally, the induction of func-
tional CD8+ T cell responses against exogenous antigens may require both antigen 
cross-presentation in MHC-I molecules to CD8+ T cells and presentation in MHC-II 
molecules to CD4+ T cells. In agreement with the classical view of antigen presenta-
tion, HSP70 also induce antigen-specific CD4+ T cell activation, as evidenced by the 
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induction of humoral immune responses and the interaction of microbial HSP70 
with HLA-DR and their peptide fragments (Haug et al. 2007). Moreover, HSP70 
chaperon both MHC-I and MHC-II epitopes (Stocki et al. 2010; 2011).
 Potential Immunomodulatory Roles of Extracellular HSP70
The fact that (i) HSP70s mediate the cross-presentation of chaperoned peptides and 
(ii) that the cross-presentation requires receptor-mediated internalization of the pep-
tide/chaperone complex, suggest that HSP70s have to be released in the extracellu-
lar milieu (Stocki and Dickinson 2012). According to their capacity to induce 
effective immune response, several studies reported that HSP70s are immunostimu-
latory molecules and, more interestingly, can induce the maturation and activation 
of dendritic cells, rendering them fully functional (reviewed in (Kuppner et al. 2001; 
Milani et al. 2002; Srivastava 2002). The term chaperokine was attributed to HSP to 
define this unique capacity of chaperons to activate immune cells (Asea et al. 2000). 
However, the intrinsic potential of HSP70s to activate APC remains a subject of 
debate (Borges et al. 2012) (see paragraph 5).
 HSP70-Binding Elements
Antigen cross-presentation requires that exogenous antigens are internalized via 
endocytic receptors [3, 4]. Accordingly, HSP70s bind to dendritic cells and macro-
phages (Arnold-Schild et  al. 1999; Todryk et  al. 1999; Wassenberg et  al. 1999) 
before being internalized in a receptor-dependent manner (Arnold-Schild et  al. 
1999; Basu et al. 2001; Binder et al. 2000; Castellino et al. 2000; Singh-Jasuja et al. 
2000; Sondermann et  al. 2000; Wassenberg et  al. 1999). Most if not all HSP70- 
binding elements identified are innate immune receptors. These results are in agree-
ment with the fact that, in an immunological point of view, extracellular HSP70 can 
be viewed (or detected) as a danger signal (modified self) released by altered/dying 
cells. These motifs are detected by the innate immune system.
By opposition to the adaptive immunity, innate immunity is defined as a non- 
antigen specific system. It is involved in numerous processes, such as antimicrobial 
activity, induction and resolution of inflammation, maintenance of tissue homeosta-
sis and wound healing. The innate immune system includes a large variety of molec-
ular and cellular actors, such as epithelial barriers, numerous soluble molecules 
(including the complement system) and innate lymphoid and myeloid cells. The 
most remarkable characteristic of innate immune cells is their capacity to discrimi-
nate self from non self (microbes) and altered or modified self (such as the detection 
of biochemical modification of cell surface molecules). The recognition of non self 
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and modified self is mediated by a restricted number of molecules (compared to the 
TCR and BCR repertoires) called pattern recognition molecules (PRM); this term is 
now preferred to the ancient nomenclature pattern-recognition receptor (PRR). 
PRM recognize microbial moieties called pathogen-associated molecular patterns 
(PAMPs) and motifs expressed by altered self and called danger-associated molecu-
lar patterns (DAMPs). Remarkably, a same PRM can detect different PAMPs and 
DAMPs and exhibiting diverse biochemical characteristics (such as nucleic acids, 
lipids, proteins or glucids). Innate immune cells also orchestrate the adaptive 
immune response via the production of soluble immune mediators (cytokines and 
chemokines) and the priming/activation of antigen-specific lymphocytes, thanks to 
the antigen-presenting functions of myeloid cells.
PRM can be classified into three families, based on their functions: (i) endocytic 
receptors, involved in ligand recognition and internalization, (ii) signaling recep-
tors, involved in ligand-induced cell activation and (iii) bridging molecules (also 
called opsonins), that bind to and favor the recognition of extracellular ligands by 
innate cells. To date, and except some individual cases, most of the HSP70-binding 
elements are endocytic and/or signaling PRM.
 Endocytic Receptors
 CD91
CD91 was the first HSP-binding element identified, initially as a gp96 receptor 
(Binder et al. 2000). CD91 was then reported as a receptor for human HSP70s on 
macrophages (Basu et al. 2001). CD91, also known as the α2 macroglobulin (A2M) 
receptor, low density lipoprotein receptor-related protein 1 (LRP1) or apolipopro-
tein E receptor (APOER), is an endocytic and signaling receptor belonging to the 
lipoprotein receptor family. CD91 is expressed by numerous cell types, including 
hepatocytes, fibroblasts, keratinocytes, smooth muscle cells and myeloid cells (Herz 
and Strickland 2001). CD91 is a multimeric receptor consisting of a 420 kDa α 
subunit, a 85 kDa β subunit and a 39-kDa associated molecule. CD91 binds to the 
activated form of α2M, a soluble molecule that binds to and inhibits a wide variety 
of proteinases and growth factors. CD91 is also suspected involved in lipid metabo-
lism and can bind, in addition to activated A2M, tissue-specific plasminogen- 
activator−inhibitor complex and urokinase-PAI1 complex.
The identification of CD91 as an HSP-binding structure was mainly based on 
competitive binding assays with the CD91 ligand A2M and with a neutralizing anti-
 CD91 mAb. The role of CD91 in HSP70-mediated antigen presentation to CD4+ 
and CD8+ T cells was confirmed by several independent studies (Fischer et  al. 
2010; Salimu et al. 2015; Tobian et al. 2004a).
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 Scavenger Receptors
Scavenger receptors represent a family of non-related cell-surface glycoproteins 
that recognize a large repertoire of ligands, ranging from bacteria and yeast to self 
(native proteins) and modified-self such as oxidized LDL (Ox-LDL) and apoptotic 
cells (reviewed in (Yamada et al. 1998; Yu et al. 2015)). Some scavenger receptors 
can also bind chemically modified LDL (acetylated LDL) that constitutes reliable 
tools in identifying HSP-binding elements, especially as binding competitors. 
Scavenger receptors thus represent an important family of endocytic PRM through 
their ability to bind endogenous and exogenous danger molecules (Jeannin et al. 
2008). Different studies reported that scavenger receptor-binding molecules, such 
as modified LDL (OxLDL or AcLDL), apoliprotein B, fucoidan and poly[IC], 
inhibited the binding of HSP70 to human APCs, suggesting that these PRM are the 
main cell surface HSP70 binding elements on human APCs (Delneste et al. 2002; 
Facciponte et al. 2007; Theriault et al. 2006; Theriault et al. 2005).
The first identified HSP70-binding scavenger receptors was SR-E1. Initially 
identified as an Ox-LDL receptor expressed by endothelial cells; this molecule, also 
known as LOX-1 or CLEC8A (C-type lectin domain family 8 member A), binds 
multiple ligands, including advanced glycation end products (AGE), activated 
platelets, and apoptotic cells. SR-E1 also binds exogenous ligands, such as virus 
and bacteria. In addition to endothelial cells, SR-E1 is constitutively expressed by 
macrophages and dendritic cells (Delneste et  al. 2002). By using a collection of 
scavenger receptor-expressing CHO cells, we have identified SR-E1 as one of the 
main HSP70-binding element on human macrophages and dendritic cells. 
Interestingly, the in vitro and in vivo cross-presentation of an antigen coupled to 
HSP70 is dependent on SR-E1 internalization (Delneste et al. 2002). Finally, the 
in vivo targeting of an exogenous antigen to SR-E1, by coupling to an anti-SR-E1 
antibody, induced an antigen-specific CD8+ T cell response (Delneste et al. 2002).
SR-E1 also exhibits features of C-type lectins (Sawamura et  al. 1997) which 
represent another important family of highly conserved PRM. Several studies have 
underlined the important role played by C-type lectins in mediating antigen cross- 
presentation, both in vitro and in vivo. Among these PRM, one can mention CD205 
(DEC205) (Bozzacco et  al. 2007) and CD209 (DC-SIGN) (Garcia-Vallejo et  al. 
2013). However, no binding of HSP70s to some other C-type lectins, such as CD209 
(Theriault et al. 2005) and CLEC7A (dectin-1), was reported so far. A binding of 
HSP70 family members was also reported to other scavenger receptors:
 – SR-A1 (Facciponte et al. 2007); SR-A1 (CD204) is a 220–250 kDa trimeric mol-
ecule that shares a collagen-like domain, essential for ligand binding. SR-A1 
binds numerous endogenous and exogenous ligands, such as AGE products, as 
well as microbes and microbial moieties.
 – SR-B1 (Fischer et al. 2010). Also known as CD36, platelet glycoprotein 4, fatty 
acid translocase (FAT) or glycoproteins 88 (GP88), IIIb (GPIIIB), or IV (GPIV), 
SR-B1 preferentially accumulates in caveolae. SR-B1 bind modified LDL 
(OxLDL and AcLDL), unmodified low density lipoproteins (LDL), very low 
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density lipoproteins (VLDL) and apoptotic cells. SR-B1 is a heavily 
N- glycosylated protein with the C-terminal cytoplasmic tail that interacts with 
the multisubunit adaptor protein PDZK.
 – SR-F1 (Facciponte et  al. 2007; Gong et  al. 2010; Theriault et  al. 2006). Also 
known as SREC-I, SR-F1 mediates the internalization of OxLDL (as well as 
AcLDL). SR-F1 can also interact with SREC-2, a homologous of SR-F1, via its 
extracellular domain; although the role played by this heterophilic interaction 
remains unclear, it is suppressed by SR-F1 ligands.
 – SR-H1 (Theriault et al. 2006). Also known as FEEL-1, CLEVER-1 or stabilin-1 
(STAB1), SR-H1 binds AcLDL, AGEs as well as Gram-negative and Gram- 
positive bacteria (Adachi and Tsujimoto 2002; Tamura et al. 2003).
These endocytic receptors are involved in the internalization and presentation 
of associated antigens to CD4+ and CD8+ T cells (Facciponte et al. 2007; Gong 
et al. 2010).
 CD40
In 2001, the group of T Lehner reported a very elegant study showing that CD40 is 
a binding and uptake receptor for Mycobacterium tuberculosis HSP70 (MtbHSP70), 
but not human HSP70 (Binder 2009; Wang et al. 2001). CD40, a membrane mole-
cule belonging to the TNF receptor superfamily (TNFRSF5), is constitutively 
expressed by APCs, including macrophages, dendritic cells and B lymphocytes. 
Triggering CD40 on myeloid cells induces the production of inflammatory cyto-
kines. The engagement of CD40 on B cells induces their maturation, antibody iso-
type switching, and their differentiation into plasma cells. The ligand of CD40 is a 
member of the TNF superfamily, TNFSF5, also called CD40 ligand (CD40L) or 
CD154. CD154 is mainly expressed by activated CD4+ T cells and acts as a costim-
ulatory molecule for B cells and myeloid cells; the engagement of CD154 partici-
pates to the T cell priming process.
A subsequent study by the same group showed that the binding of MtbHSP70 to 
the extracellular domain of CD40 was localized in the N-terminal nucleotide- 
binding domain in its ADP (peptide-binding) state (Becker et al. 2002). To date, 
CD40 has been mainly reported as a signaling receptor (reviewed in (Banchereau 
et al. 1994); its role in myeloid cell activation by HSP70 is discussed in the para-
graph “Signaling receptors”.
 C-type Lectins
As mentioned above, HSP70 can bind to the C-type lectin/scavenger receptor SR-E1 
which is constitutively expressed on myeloid cells. Studies have also reported that 
HSP70 can bind to the C-type lectin CD94 (Gross et al. 2003a; Moser et al. 2002). 
CD94/NKG2 is a family of receptors mainly expressed on natural killer (NK) cells 
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and a subset of CD8+ T cells. The consequences of HSP70 binding to CD94 on the 
biology of NK cells is detailed in the paragraph 4.
 Signaling Receptors
HSP70 can efficiently cross-prime naive T cells, a process that required an optimal 
activation of APCs. However, some of the endocytic receptors identified are not 
signaling molecules, such as SR-E1, suggesting that signaling receptors are recruited 
by HSP70s. Numerous studies were thus focused on identifying HSP70 signaling 
receptors.
 TLRs
Through their pivotal role in the activation of myeloid APCs, members of the Toll- 
like receptor (TLR) family are crucial in the initiation of innate and adaptive immune 
responses. The induction of in vivo immune responses by HSP70 suggested that 
they can activate myeloid cells and members of the TLR family rapidly emerged as 
candidate molecules. TLRs are type I integral membrane glycoproteins belonging to 
the IL-1 receptor (IL-1R) superfamily. TLR and IL-1R have a conserved region of 
≈ 200 amino acids in their cytoplasmic domain, known as Toll/IL-1R (TIR) domain. 
The TIR domain is required for the intracellular signaling induced by TLR ligands. 
TLR can sense a large variety of microbes and microbial moieties, as well as host 
motifs. They are localized either at the cell surface or in endosomes where there are 
specialized in detecting microbes or nucleic acids, respectively. After ligand bind-
ing, TLRs dimerize and undergo a conformational change required for the recruit-
ment of downstream signaling molecules that include the adaptor molecule myeloid 
differentiation primary-response protein 88 (MyD88), IL-1R-associated kinases 
(IRAKs), TGFβ-activated kinase (TAK1), TAK1-binding protein 1 (TAB1), TAB2 
and TNF-receptor-associated factor 6 (TRAF6). The engagement of TLRs gener-
ates potent activation signals for myeloid cells, as evidenced by the production of 
numerous pro-inflammatory cytokines, chemokines and interferons (IFNs). TLR 
agonists also induce the maturation of dendritic cells, a process required for naïve T 
cell priming. TLR agonists may also participate to the activation of innate and con-
ventional lymphoid cells.
Asea et al. reported that TLR2/TLR4 are involved in the activation of myeloid 
cells by HSP70 (Asea et  al. 2000, 2002), as evidenced by the production of the 
inflammatory cytokines IL-1β, TNFα and IL-12, and an elevated expression of the 
costimulatory molecule CD86. The HSP70-induced signaling was mediated via the 
MyD88/IRAK/NF-kB signaling pathway. The role played by TLR4 in the activation 
of dendritic cells and in the induction of a Th1 response by HSP70s was confirmed 
by others (Fang et al. 2011).
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TLR4 was initially described as an element of the multimeric LPS receptor 
which includes, in addition to TLR4, the binding elements CD14 and LBP and the 
accessory molecule MD2. Accordingly, the activation of APCs induced by HSP70 
requires CD14, in addition to TLR4; however, no data supported a direct binding of 
HSP70 to CD14 (Asea et al. 2000; Moroi et al. 2000). In line with the capacity of 
HSP70 to signal via TLR2/TLR4, several endogenous ligands have reported to bind 
to these molecules, including, in addition to other HSP (HSP60, HSP96), HMGB1, 
surfactant protein D (SP-D), fibrinogen, fibronectin, and hyaluronic acid (Bryant 
et al. 2015).
 CD91
CD91 is phosphorylated in response to HSP, triggering signaling cascades that ulti-
mately lead to the activation of NF-κB (Pawaria and Binder 2011). The stimulatory 
function of CD91 was confirmed in another study showing that the proliferation and 
cytokine production by CD4+ T cells in response to APC pulsed with complexes 
between HSP70 and antigenic peptides was inhibited by CD91 siRNA (Fischer 
et al. 2010). Accordingly, the CD91 ligand A2M acts as an adjuvant to prime CD8+ 
T cells in vivo (Kropp et al. 2010).
 CD40
MtbHSP70 induced a CD40-mediated production of numerous cytokines and che-
mokines, such as CCL3 (MIP1α) involved in the recruitment and activation of poly-
morphonuclear cells, CCL4 (MIP1β) chemotactic for numerous immune cells and, 
CCL5 (RANTES), chemotactic for T cells. This property can be explaind by the 
adjuvanticity of MtbHSP70 (Wang et al. 2001). The binding of MtbHSP70 to CD40 
induces an intracellular signaling via p38, associated with the internalization of the 
complex HSP70-CD40. P38 is a transduction molecule involved in the signaling 
cascade downstream CD40 that is involved in the production of pro-inflammatory 
cytokines, such as TNFα and IFNγ (Pullen et al. 1999).
 CCR5
C-C chemokine receptor type 5 (CCR5), also known as CD195, acts as a receptor 
for the C-C chemokines CCL3, CCL4, and CCL5, three chemokines induced by 
MtbHSP70. CCR5 is mainly involved in the attraction of T cells in specific tissues 
and organs. The signaling via CCR5 induces dendritic cell activation and aggrega-
tion and participates to the formation of the immune synapse between dendritic 
cells and T lymphocytes (Floto et al. 2006). The binding of MtbHSP70 to CCR5 
induces a Ca2+ signaling and the engagement of CCR5 participates in the 
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generation effector immune responses (MacAry et  al. 2004). In this study, the 
authors showed that the activation by MtbHSP70 was not dependent on TLR 
signaling.
 Cooperation Between Endocytic and Signaling Receptors
Except some HSP70-binding elements, such as CD91 and CD40 which can act as 
both endocytic and signaling receptors, several studies suggest that the activation of 
innate immune cells by HSP70 requires cooperation between an endocytic receptor 
and a signaling receptor. This mechanism of interaction is observed in several 
examples of innate immune cell activation by non self and altered self. Nevertheless, 
in most cases, this model is supported by indirect in vivo experiments using HSP70 
as a vaccine carrier molecule. As an example, Gong et al have demonstrated that the 
induction of antitumor immunity by HSP70 isolated from tumor-dendritic cell 
fusions is dependent on functional SR-F1 and TLR2/TLR4 expression by dendritic 
cells (Gong et al. 2009). In a similar manner, we have reported that targeting in vivo 
a vaccine antigen to SR-E1 is not sufficient to induce a protective antitumor response 
and that protection was only observed when antigen targeting was associated with 
the use of a TLR-activating adjuvant (Delneste et al. 2002). Interestingly, Mizukami 
et al showed that the cross-priming capacity of HSP70s was mediated by a TLR- 
independent mechanism, while the MyD88/IRAK signaling was required to induce 
tumor rejection (Mizukami et al. 2012).
 Hsp70 in the Regulation of Innate Immune Cell Activation
HSP70s, as other members of the HSP superfamily, induce antigen-specific immune 
responses, in vitro and in vivo, a process that requires activation of APCs. As a con-
sequence, several studies have reported that HSP70 induce the activation of innate 
immune cells, and especially myeloid cells.
 Activation of Myeloid Cells
In addition to their role as sentinels of the innate immune system, macrophages and 
dendritic cells also act as professional antigen-presenting cells. Although macro-
phages are only able to present antigens to memory T cells, dendritic cells have the 
unique capacity to prime naive T cells.  HSP70s can induce not only the cross- 
presentation but also the presentation of chaperoned peptides and coupled antigens 
to CD4+ and CD8+ T cells. The fact that HSP70s induce protective immune CD4+ 
and CD8+ T cell responses suggests that they are able to activate APCs. It is 
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important to mention that antigen presentation and cross-presentation induced by 
HSP70s involve the same endocytic and signaling receptors. As an example, CD91 
and scavenger receptors are involved in the activation of antigen-specific memory 
CD4+ T cells (Fischer et al. 2010). The role of HSP70 in the induction of CD4+ T 
cells has been also reported by other studies (Mycko et al. 2004; Tobian et al. 2004a, 
b; Wang et al. 2006).
As mentioned above, extracellular HSP70s induce the production of pro- 
inflammatory cytokines (TNFα, IL-1β, IL-6) and C-C chemokines by myeloid cells 
(Asea et  al. 2000, 2002; Redzovic et  al. 2015; Wang et  al. 2001). HSP70s also 
induce the production of IL-12 (Vabulas et al. 2002), a pro-Th1 cytokine, and of 
IL-15 (Redzovic et al. 2015), a cytokine involved in the activation of innate and 
adaptive cytotoxic lymphoid cells, as well as type I IFNs by plasmacytoid cells 
(Jacquemin et al. 2017). The activation of myeloid cells is also associated with an 
increase of expression of MHC-II and of the costimulatory molecules CD40, CD80 
and CD86 (Asea et al. 2002; Fang et al. 2011; Wang et al. 2002) which provide 
stimulatory signals required for optimal T cell activation.
Interestingly, HSP70s were reported to induce dendritic cell maturation (Kuppner 
et al. 2001; Vabulas et al. 2002; Wang et al. 2002), a process required to prime naive 
T cells against neo-antigens. Importantly, the capacity of HSP70 to activate and 
induce the maturation of dendritic cells supports their ability to generate immune 
responses in vivo, in the absence of adjuvant (Srivastava et al. 1998). As a conse-
quence of their dendritic cell-stimulatory activity, HSP70s have been reported able 
to convert T cell tolerance to autoimmunity in vivo, in a murine model of model of 
autoimmune diabetes (Millar et al. 2003). Studies also reported that an intratumoral 
infusion of HSP70 increase the infiltration of cytotoxic lymphoid and the produc-
tion of IFNγ (Shevtsov et al. 2014).
 Activation of Innate Lymphoid Cells
NK cells are innate lymphoid cells that play a pivotal role in the destruction of 
virus-infected cells and tumoral cells. Their activation is dictated by a delicate bal-
ance between stimulatory and regulatory signals (Narni-Mancinelli et al. 2013). The 
overexpression of HSP70 by tumor cells has been reported as a marker of tumor 
immunogenicity (Clark and Menoret 2001) and in vivo studies showed that tumors 
secreting HSP70s display increased immunogenicity, with induction of strong and 
specific CTL responses (Massa et al. 2004). Interestingly, CD94+ CD3- NK cells 
can recognize and kill membrane HSP70-positive tumor cells in a granzyme- 
dependent manner (Moser et  al. 2002; Multhoff et  al. 1995). The interaction of 
HSP70 with CD94 was demonstrated by competitive binding experiments (Gross 
et al. 2003a, b).
Moreover, in the absence of HLA-E expression, the activation of NK cells with 
the HSP70 peptide TKD render them cytotoxic against target cells (Bottger et al. 
2012; Gross et al. 2008). More intriguingly, Massa et al reported that the interaction 
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of HSP70 with NK cells may also participate in the initiation of antigen-specific T 
cell responses. More precisely, the authors demonstrated that the adjuvant activity 
of HSP70 requires NK cells at the site of dendritic cell-HSP70 interaction whereas 
its ability to induce antigen cross-presentation of chaperoned peptides is  independent 
of NK cells (Massa et al. 2005). A recent study reported that HSP70-positive exo-
somes derived from genotoxic drug-treated tumor cells induce the production of 
cytokines by CD56high NK cells in a TLR2-dependent manner (Vulpis et al. 2017).
 The Immune Properties of HSP70: An Unsolved Mystery
Innate immunity receptors act as immune sensors able to discriminate self from 
non-self and modified self. In most cases, the elimination of modified self does not 
activate immune cells, maintaining tissue homeostasis and preventing the initiation 
of a potentially harmful autoimmune response. Internalization without recruitment 
of a signaling receptor may lead to tolerance, as reported for the internalization of 
apoptotic cells. As an example, the interaction of TSP-1 with CD91 and CD36, two 
HSP70-binding elements, may participate to the tolerogenic status of dendritic cells 
after apoptotic cell phagocytosis (Poon et al. 2014). In agreement with these studies, 
the presentation of apoptotic-cell-derived antigens requires the presence of a TLR 
agonist in the same cargo as that of apoptotic cells (Blander and Medzhitov 2006).
However, most of innate endocytic receptors also recognize non self (microbes 
and microbial moieties) that induce a huge activation of immune cells. The concept 
of cooperation between endocytic and signaling receptors has thus emerged to 
explain this dichotomy. Innate cell activation induces the recruitment of signaling 
PRM after the binding of ligands to the endocytic receptor. In a similar manner, 
HSP70 endocytosis precedes signaling in myeloid cells (Kuppner et al. 2001; Moroi 
et  al. 2000). In contrast to early apoptotic cells, necrotic cells induce a pro- 
inflammatory response, thanks to the release of stimulatory endogenous molecules 
called alarmins. These alarmins, such as HMGB1, IL-33 and ATP, activate immune 
cells and participate in the initiation of antigen-specific immune responses. Based 
on the studies showing that HSP70s activate APCs, it has been proposed that HSP70 
may be considered as a danger signal. However, other authors refute to classify 
HSP70 as a DAMP (van Eden et al. 2012). Indeed, circulating HSP70 are detected 
in the serum of healthy subjects, without signs of inflammation. Moreover, different 
studies argue that the stimulatory activities of HSP70s are associated to the presence 
of contaminating molecules in HSP70 preparation.
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 Do HSP70 Interact with a Limited Number of Receptors?
To date, HSP70s have been reported to interact with a large variety of immune 
receptors. However, and even though most studies concur to recognize that HSP70 
are able to induce antigen (cross) presentation, different studies refuted the HSP70- 
binding capacity to some receptors. Although this initial study was confirmed by 
subsequent studies (Binder and Srivastava 2004; Salimu et al. 2015), authors con-
tested the fact that CD91 may be considered as an HSP-binding structure, either by 
using CD91null cells or by demonstrating that the binding of HSP to CD91 was not 
altered by the conventional CD91 ligand activated α2 macroglobulin (A2M*) or the 
CD91 antagonist molecule, receptor-associated protein (RAP) (Berwin et al. 2002). 
Moreover, although highly expressed on macrophages, the expression of CD91 is 
very low on dendritic cells, suggesting that its role in in vivo T cell priming should 
be marginal. Moreover, Theriault et al. reported that scavenger receptors, but not 
CD40 and CD91, are the main HSP70-binding elements (Theriault et al. 2005). In a 
similar manner, Bendz et al have shown that the cross-presentation capacity of dif-
ferent dendritic cell subsets was equivalent, irrespective of the level of CCR5 
expression (Bendz et al. 2008).
HSP70 are endogenous molecules that, theoretically, cannot activate APCs. 
Nevertheless, several studies reported that HSP70s can directly activate myeloid 
cells (and, at a lower extent, lymphoid cells) via innate receptors, such as TLR4. All 
the studies reporting a direct stimulatory activity of HSP70 claimed that this process 
was independent of contaminating molecules, especially endotoxins (Wang et al. 
2010). However, independent studies reported that contaminating endotoxins were 
responsible for the activation of myeloid cells (Bausinger et al. 2002; Gao and Tsan 
2003, 2004). Another study reported that calcium signaling induced by human 
HSP70 and MtbHSP70 may be caused by contaminating nucleotides (Bendz et al. 
2008).
 The Immunoregulatory Properties of HSP70
HSP70s are highly conserved molecules which can be released in the extracellular 
milieu. Consequently, the initiation of HSP70-specific immune responses remains 
exceptional. Contrary to the vast majority of studies, some authors have reported 
that HSP70 exhibit regulatory properties (reviewed in (Borges et al. 2012; van Eden 
et  al. 2005). The initial study on a potential regulatory role for HSP70s was the 
demonstration that MtbHSP70 has an anti-inflammatory role in an in vivo model of 
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autoimmune arthritis model (van Eden et al. 1998). The anti-inflammatory and pro-
tective roles of HSP70s and of selected HSP70 peptides have been thereafter 
reported in different models of severe or chronic inflammation (Vinokurov et al. 
2012; Yurinskaya et  al. 2009), infection (Kimura et  al. 1998) and skin allografts 
(Borges et al. 2010). Extracellular HSP70s also induce endotoxin tolerance in mac-
rophages (Aneja et al. 2006).
At the cellular level, HSP70 have been also reported to inhibit the maturation of 
dendritic cells, to induce the differentiation of monocyte-derived dendritic cells into 
tolerogenic cells (Motta et al. 2007; Stocki and Dickinson 2012) and to potentiate 
the suppressive activity of myeloid derived suppressive cells (MDSC) (Diao et al. 
2015). By inducing suppressive myeloid cells, HSP70s increase the immunosup-
pressive activity of CD4+ CD25+ FoxP3+ regulatory T cells (Wachstein et  al. 
2012); regulatory T cells (Treg) have the unique capacity to dampen inflammation 
and to maintain an immunoregulatory environment (Josefowicz et al. 2012). HSP70s 
also favor the production of immunosuppressive Th2 cytokines by CD4+ T cells 
(Tsan and Gao 2004).
Macrophages are involved in numerous processes, such as immune surveillance 
and wound healing. A binary classification has thus been proposed to define their 
functional polarization with M1 and M2 cells representing the extremes of a con-
tinuum of polarization profiles. M1 cells exhibit antimicrobial and antitumor prop-
erties while M2 cells, mainly involved in tissue homeostasis and repair, exhibit 
immunoregulatory and protumoral properties. In established solid tumors, tumor- 
associated macrophages (TAM) exhibit a M2 phenotype (Mantovani et al. 2017). As 
examples, SR-A1 promotes tumor progression in murine models of ovarian and 
pancreatic cancer (Neyen et al. 2013a, b). HSP70s favor the polarization of macro-
phages into regulatory M2 cells (Lopes et al. 2014). An intriguing study recently 
reported that HSP70 regulates the M2-like polarization of tumor-associated macro-
phages in a SR-A1-dependent manner, favoring in vivo glioma regression (Zhang 
et al. 2016). However, whether this mechanism can be extended to other HSP70- 
binding elements, and especially scavenger receptors and C-type lectins, remains 
unknown.
The immunoregulatory activity of HSP70 was demonstrated to be dependent on 
the induction of the suppressive cytokine IL-10 by myeloid cells ((Detanico et al. 
2004; Kimura et  al. 1998; van Eden et  al. 2005; Wendling et  al. 2000). HSP70- 
induced IL-10 may then favor the generation of regulatory cells (Treg) as Treg cell 
depletion completely abolished this effect (Hauet-Broere et al. 2006). The capacity 
of HSP70 to favor a M2 polarization was also suspected dependent on the induction 
of IL-10 (Lopes et al. 2016). More recent studies have shown that the capacity of 
HSP70 to inhibit the production of IL-10 is driven by a down-regulation of the tran-
scription factors C/EBPβ and C/EBPδ (Borges et al. 2013); this inhibition was cor-
related with a decreased production of pro-inflammatory cytokines and abrogated 
upon pretreatment of cells with ERK and JAK2/STAT3 inhibitors. These results are 
in agreement with studies reporting the pivotal role played by STAT3 in the estab-
lishment of an immunoregulatory environment (Yu et al. 2007). More intriguingly, 
Chandarwakar et al reported that the regulatory versus stimulatory activity of HSP 
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was dependent on their concentrations with low doses being efficient to initiate 
antitumor immune responses and high doses being inefficient or even immunosup-
pressive (Chandawarkar et al. 1999).
 Can SIGLEC4/15 Reconciliate Stimulatory and Regulatory 
Immune Properties of HSP70?
In 2015, Fong et al reported that the immune properties of extracellular HSP70s are 
mediated via the receptors Siglec-5 and Siglec-14 (Fong et al. 2015). Siglecs are 
transmembrane sialic acid-binding immunoglobulin-like lectins mainly expressed 
on leukocytes (Macauley and Paulson 2014; Schwarz et  al. 2015). Siglec-5 and 
Siglec-14 belong to the rapidly evolving CD33-related Siglecs (CD33rSiglecs) fam-
ily (Angata 2006). Siglec-5 and Siglec-14 are immune-suppressive and immune- 
activating paired receptors. This study reported that HSP70s bind Siglec-5 and 
Siglec-14 in a sialic-acid independent manner and that Hsp70 suppresses inflamma-
tion through Siglec-5 while, in contrast, its augments inflammation through 
Siglec-14. Interestingly, Siglec-5 and Siglec-14 can interact with other HSP70- 
binding elements, such as TLR and scavenger receptors/C-type lectins which have 
been defined as HSP70-binding elements. In addition to shed new light on the com-
plexity of the biology of extracellular HSP70, this study provides an elegant molec-
ular demonstration of the dichotomous immune properties of HSP70s and may help 
clarifying contradictory studies on the immune properties of HSP70s.
 HSP70-Based Strategies to Induce Protective Immune 
Responses
Even though the intrinsic immune properties of HSP70 remain unclear, most authors 
agree on the fact that HSP70s represent unique vehicles to induce protective antitu-
moral and antimicrobial CD8+ and CD4+ T cell responses in vivo (Blachere et al. 
1997; SenGupta et al. 2004; Udono et al. 1994; Udono and Srivastava 1993), thanks 
to their capacity to carry exogenous antigens into MHC-I and MHC-II antigen pre-
sentation pathways in professional APCs (Castellino et al. 2000; Srivastava 2002). 
Accordingly, different vaccine strategies have been proposed based on these unique 
immune properties. A recent review summarized some ongoing antitumoral vaccine 
clinical trials using HSP (Shevtsov and Multhoff 2016). In this paragraph are only 
mentioned the different HSP70-based vaccine strategies to induce protective antitu-
mor and antiviral immune responses.
The initial HSP70-based vaccine strategies relied on the peptide-biding capacity 
of HSP. Vaccines contained HSP70 isolated from tumor (or virus infected) cells 
(Noessner et al. 2002). In this approach, the antigen specificity is determined by the 
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chaperone-assisted peptides, allowing proposing individual vaccines irrespective of 
the nature of the vaccine antigens and of the MHC restriction (Suto and Srivastava 
1995). HSP70s can be also isolated from the supernatants of apoptotic or stressed 
tumor cells (Chen et al. 2009; Masse et al. 2004) or from HSP70-transfected tumor 
cells (Massa et al. 2004). An original approach was the use of HSP70 isolated from 
dendritic/tumor cell fusion which induce potent antigen-specific antitumor immune 
responses, superior to the one of HSP70 isolated from tumor cells. (Enomoto et al. 
2006). Another peptide-based approach is to reconstitute HSP-peptides complexes 
with immunodominant tumor antigen peptides (Blachere et al. 1997). Vaccinations 
with dendritic cells pulsed with tumor-derived HSP70 can also induce protective 
immune responses (Toomey et al. 2008).
Other strategies are based on the capacity of HSP70 to target dendritic cells 
in vivo, allowing the antigen to get access to the antigen presentation pathways. In 
this case, HSP70, coupled to the vaccine antigen, is used as a vaccine vehicle. 
Vaccine antigens can be chemically coupled to HSP70 (Delneste et  al. 2002) or 
produced as a recombinant fusion molecule (Zhang and Huang 2006). Fusion pro-
teins, consisting in HSP70 coupled to a vaccine antigen, have been validated using 
several different tumor antigens, such mesothelin, MAGE-1, PSA, carcinoembyonic 
antigen and Her2/neu (Ge et al. 2009; Yuan et al. 2014; Dong et al. 2013; Jiang et al. 
2013; Pakravan et al. 2010; Wu et al. 2005) as well as viral antigens, such as the 
HPV16 E7 antigen and a dominant epitope of the EBV latent protein 2A (Zong 
et al. 2009, 2013).
Based on its immunostimulatory properties, other strategies use HSP70s as an 
adjuvant molecule for vaccines using tumor cell lysates (Wang et al. 2010; Li et al. 
2010) or DNA vaccines as a source of antigens (Li et al. 2007; Zhang et al. 2007; 
Farzanehpour et al. 2013; Garrod et al. 2014) or in classical subunit vaccines (Lewis 
et  al. 2014; Li et  al. 2010; Shevtsov et  al. 2014) to initiate effective immune 
responses. Nevertheless, in order to ameliorate the efficacy of the vaccine or to 
overcome the tumor immunosuppressive environment, several studies associated 
HSP70 vaccines with an adjuvant. In most cases, combining HSP70 vaccine with 
adjuvant (Delneste et al. 2002) or CD40L (Gao et al. 2012) induced more potent 
protective immune responses.
 Conclusions
The identification of tumor-associated antigens and the presence of circulating 
tumor specific cytotoxic T lymphocytes (CTLs) in tumor-bearing patients suggested 
that initiating a protective antitumor immune response is feasible. A lot of work was 
thus done to propose antitumor vaccine strategies, such as the use of recombinant 
virus encoding human tumor antigens, tumor cell-derived exosomes or nucleic acid- 
based vaccines. Following the identification of the antigen cross-presentation pro-
cess, numerous studies aimed at identifying carrier proteins that may selectively 
target and activate immature dendritic cells in vivo. HSP70s have thus emerged in 
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the 1990s as powerful vaccine vehicles to initiate potent and protective antitumoral 
(and antiviral) CD8+ T cell immune responses. This remarkable property is related 
to the ability of extracellular HSP70s to interact with innate immune receptors 
involved in antigen cross-presentation. The initiation of an antigen-specific CD8+ T 
cells response against a neo-antigen requires that dendritic cells are fully activated. 
In agreement with their vaccine potentials, the initial studies suggested that HSP70s 
are intrinsically able to activate APCs. However, the exact nature of PRM involved 
in the immune properties of HSP70s remains, to date, controversed. Members of the 
scavenger receptor family appear as the less discussed endocytic receptors. 
Contrastingly, whether HSP70s are suppressive or stimulatory molecules remain 
debated. Based on the current view of the capacity of the innate immune system to 
maintain immune homeostasis in response to modified self, one could hypothesize 
that HSP70s are not stimulating molecules. Nevertheless, to precisely determine the 
immune status of HSP70s remains a big challenge that would allow reevaluating 
their therapeutic use.
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